- Home
- PHVS
PHVS
Pharvaris N.V.
as 02-04-2025 3:36pm EST
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
| Founded: | 2015 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $41.60 | AVG Volume (30 days): | 49.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.21 - $33.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pharvaris N.V. News
PHVS Breaking Stock News: Dive into PHVS Ticker-Specific Updates for Smart Investing
Insider Monkey
5 days ago
Why Pharvaris (PHVS) Is Advancing Today
Insider Monkey
13 days ago
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now?
GlobeNewswire
23 days ago
Pharvaris Outlines 2025 Strategic Priorities
TipRanks
2 months ago
Pharvaris price target lowered to $46 from $50 at JMP Securities
GlobeNewswire
3 months ago
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
GlobeNewswire
3 months ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewswire
3 months ago
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
GlobeNewswire
4 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Compare PHVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.